Polymorphic CYP2A6 and its clinical and toxicological significance

This publication has 13 references indexed in Scilit:

• Summary of information on human CYP enzymes: human P450 metabolism data
  Drug Metabolism Reviews, 2002
• An in Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 Alleles
  Biochemical and Biophysical Research Communications, 2002
• A polymorphism (A118G) in the μ-opioid receptor gene affects the response to morphine-6-glucuronide in humans
  Pharmacogenetics, 2002
• Polymorphisms of CYP2A6 and its practical consequences
  British Journal of Clinical Pharmacology, 2001
• Identification of a Single Nucleotide Polymorphism in the TATA Box of the CYP2A6 Gene: Impairment of Its Promoter Activity
  Biochemical and Biophysical Research Communications, 2001
• Duplications and Defects in the CYP2A6 Gene: Identification, Genotyping, and In Vivo Effects on Smoking
  Molecular Pharmacology, 2000
• CYP2A6: a human coumarin 7-hydroxylase
  Toxicology, 2000
• Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism
  FEBS Letters, 1999
• Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
  Trends in Pharmacological Sciences, 1999
• GENETIC EPIDEMIOLOGY OF ENVIRONMENTAL TOXICITY AND CANCER SUSCEPTIBILITY: HUMAN ALLELIC POLYMORPHISMS IN DRUG-METABOLIZING ENZYME GENES, THEIR FUNCTIONAL IMPORTANCE, AND NOMENCLATURE ISSUES
  Drug Metabolism Reviews, 1999